Research Topics
Genomes and Genes | John D ShaughnessySummaryAffiliation: University of Arkansas for Medical Sciences Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profileChen Zhao
The Center for Bioinformatics and The institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, 200241, China
BMC Genomics 12:S3. 2011..Fine-tuning of model parameters and optimizing each step of the modeling process often results in over-fitting problems without improving performance...- Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasiaEun Sung Park
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
BMC Genomics 8:302. 2007.... 
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profilingJohn D Shaughnessy
Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Immunol Rev 194:140-63. 2003..Here, we discuss recent progress made in addressing many of the above issues through the molecular dissection of the transcriptome of normal PCs and MM...- Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myelomaJohn Shaughnessy
Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Hematology 10:117-26. 2005..Based on these data we conclude that over-expression of CKS1B, mainly due to gene amplification, imparts a poor prognosis in MM, possibly as a result of enhanced degradation of p27Kip1... - A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1John D Shaughnessy
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 109:2276-84. 2007..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions... - Global gene expression profiling in the study of multiple myelomaJohn D Shaughnessy
Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences Little Rock, Arkansas 72205, USA
Int J Hematol 77:213-25. 2003.... - Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy IIJohn Shaughnessy
Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 120:44-52. 2003..02 and 0.1 respectively) and should be part of the initial work-up of patients with MM... - Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen
The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 115:61-70. 2010..Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib... - High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2Yiming Zhou
Donna D and Donald M Lambert Laboratory for Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Proc Natl Acad Sci U S A 107:7904-9. 2010..Silencing of AGO2 dramatically decreased viability in MM cell lines. Genome-wide elevated expression of miRNAs in high-risk MM may be secondary to deregulation of AGO2 and the enzyme complexes that regulate miRNA maturation and function... - Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenanceBijay Nair
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 115:4168-73. 2010..The robustness of the GEP risk model should be exploited in clinical trials aimed at improving the notoriously poor outcome in high-risk disease... - Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survivalBijay Nair
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
Blood 113:6572-5. 2009..001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma... - International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocolsSarah Waheed
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 117:1001-9. 2011.... - RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myelomaSiqing Wang
The Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR, USA
Blood 114:600-7. 2009..These findings provide a rationale for RA-based therapy in aggressive RARalpha2(+) MM... - Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone diseaseAngela Pennisi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 145:775-87. 2009..These data demonstrated that DASH proteases are involved in myeloma bone disease and tumour growth... - Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myelomaYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 112:196-207. 2008.... - Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3Bart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 138:176-85. 2007..Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients... - Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyFrits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 116:1220-7. 2010.... 
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profileYiming Zhou
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham 816, Little Rock, AR 72205, USA
Br J Haematol 145:637-41. 2009..42, P = 0.004). The prevalence of high-risk myeloma in the RS+/FL+ group may reflect a dissemination-prone condition not shared by the other three groups...- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2Mauricio Pineda-Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 140:625-34. 2008..Our data strongly suggest that the addition of bortezomib in TT3 was accountable for its superior performance rather than greater compliance with protocol completion as a result of greater dose-density in TT3 vs. TT2... - Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda Roman
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 136:393-9. 2007..In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM... - Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisFenghuang Zhan
Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Blood 109:1692-700. 2007..01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias... - Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:3122-5. 2008..Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382... - TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 147:347-51. 2009..FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent... - Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implicationsRonald Walker
Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Clin Oncol 25:1121-8. 2007..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)... - Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:3115-21. 2008..008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well... - The molecular classification of multiple myelomaFenghuang Zhan
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 108:2020-8. 2006..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature... - Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myelomaFrits van Rhee
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
Mol Cancer Ther 8:2616-24. 2009.... - Prediction of cytogenetic abnormalities with gene expression profilesYiming Zhou
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 119:e148-50. 2012..The model has an accuracy rate up to 0.89. These results provide proof of concept for the hypothesis that gene expression profiling is a superior genomic method for clinical molecular diagnosis and/or prognosis... - Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneXin Li
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Stem Cells 29:263-73. 2011..This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis... - Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment armsBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Clin Oncol 28:3023-7. 2010..After further follow-up of 87 months, we examined, in reiterative analyses, the effect of increasing time intervals on clinical outcomes relevant to baseline prognostic variables and treatment randomization... - Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous boneAngela Pennisi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
PLoS ONE 5:e15233. 2010..Current management of myeloma bone disease is limited to the use of antiresorptive agents such as bisphosphonates... - CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanismsFenghuang Zhan
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
Blood 109:4995-5001. 2007.... - The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsSimona Colla
Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Blood 109:4470-7. 2007..We conclude that specific strategies to modulate persistent activation of the JNK pathway may be beneficial in preventing disease progression and treating myeloma-associated bone disease by inhibiting DKK1 expression... - Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock AR, USA
Blood 118:3512-24. 2011..We are investigating whether second-generation proteasome inhibitors (eg, carfilzomib) can overcome resistance associated with high PSMD4 levels... - The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growthAngela Pennisi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 114:1803-12. 2009..Myeloma cells expressed low to undetectable ephrinB2 and EphB4 and did not respond to the chimeric proteins. The ephrinB2/EphB4 axis is dysregulated in MM, and its activation by EphB4-Fc inhibits myeloma growth and bone disease... - Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myelomaYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Br J Haematol 148:726-38. 2010.... - An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationOwen W Stephens
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 119:503-12. 2012.... - Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsJohn D Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 137:530-6. 2007.... - Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myelomaErming Tian
The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Mol Cancer Ther 7:500-9. 2008..Collectively, our data suggest that EPED3 targets mitochondrial function to rapidly deplete chemical energy and initiate apoptosis in myeloma cells at nanomolar concentrations while leaving stromal cells unharmed... - Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
Cancer 113:355-9. 2008..Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma... - Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoShmuel Yaccoby
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 109:2106-11. 2007..We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth... - An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myelomaWei Xiong
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Blood 112:4235-46. 2008..These data suggest that loss of TP53 expression in MM confers high risk and probably results in the deregulation of a novel set of MM-specific TP53-target genes. TP53 target gene specificity may be unique to different cell lineages... - F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel
Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 114:2068-76. 2009..Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy... - The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myelomaErming Tian
Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, College of Medicine, University of Arkansas for Medical Sciences, Little Rock 72205, USA
N Engl J Med 349:2483-94. 2003..Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both... - Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signalingYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 113:4319-30. 2009.... - The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myelomaSarah K Johnson
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Int J Hematol 94:321-33. 2011..This brief review will focus on the use of GEP of MM to define high-risk myeloma, and elucidate underlying mechanisms that are beginning to change clinical decision-making and inform drug design... - Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantationJumei Shi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 143:641-53. 2008..Encouragingly, 50% of patients achieved (near) complete remission. These data set the stage for future studies of KIR-ligand mismatched NK cell therapy in the autologous setting... - Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell linesXin Li
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 138:802-11. 2007..These myeloma cell lines and the procedures used for their establishment provide essential tools for studying myeloma biology and therapy... - First thalidomide clinical trial in multiple myeloma: a decadeFrits van Rhee
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 112:1035-8. 2008..The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma... - Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatioIchiro Hanamura
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham St. #776, Little Rock, AR 72205, USA
Blood 108:1724-32. 2006..027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis... - Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survivalYun Ge
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Br J Haematol 133:83-92. 2006..Our results indicate that FAP is critical for the interaction of MM cells with the BM microenvironment--a potential therapeutic target in myeloma... - Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck
University of Arkansas for Medical Sciences, Little Rock, AR, USA
Clin Cancer Res 18:5499-506. 2012.... - Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growthYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 77205, USA
Blood 112:374-82. 2008..These results provide further support of the potential anabolic and anti-MM effects of enhancing Wnt signaling in the bone... - Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myelomaYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Bone 42:669-80. 2008..Dkk1 inhibits this process and may be a key factor regulating pre-osteoblast differentiation and myeloma bone disease... - Using genomics to identify high-risk myeloma after autologous stem cell transplantationJohn D Shaughnessy
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Biol Blood Marrow Transplant 12:77-80. 2006..Synergy between cyclin D2 and CKS1B, but not cyclin D1 and CKS1B, may lead to early treatment failure... - Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISHBart Barlogie
Myeloma Institute for Research and Therapy, USA
Int J Hematol 76:337-9. 2002..Thus, both cytogenetics and FISH are recommended in the initial evaluation of patients with MM... - Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myelomaDaisy Alapat
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Am J Clin Pathol 137:93-100. 2012..CD200 is expressed in several hematolymphoid neoplasms. Analysis of its expression has several diagnostic and potentially prognostic applications in the flow cytometric evaluation of lymphoid malignancies... - Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Br J Haematol 135:158-64. 2006..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma... - Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myelomaJumei Shi
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 111:1309-17. 2008..Our findings have clear therapeutic implications for MM and other NK cell-sensitive malignancies in the context of both allogeneic and autologous adoptively transferred NK cells... - Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphomaAmy Heerema-McKenney
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, USA
Am J Clin Pathol 133:265-70. 2010..Most cases share a common GEP signature dominated by hyperexpression of cyclin D1 or cyclin D3 genes, with increased expression of the B-cell genes CD20 and VPREB3... - Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsKatie Stone
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
PLoS ONE 8:e54610. 2013..These data suggest that interleukin-6 receptor polymorphism may be a contributing factor in Castleman Disease, and further research is warranted... - The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotypeClive S Zent
Division of Hematology Oncology, Central Arkansas Healthcare System and University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
Leuk Res 27:765-74. 2003..CLL and MM differentially expressed 18% of 130 apoptosis related genes, suggesting differences in mechanisms of cell survival... - Clinical use of genomics in multiple myelomaJohn D Shaughnessy
Division of Basic Sciences, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, USA
Clin Adv Hematol Oncol 4:419-21. 2006 - Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myelomaJohn D Shaughnessy
Donna D. and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
Int J Hematol 76:59-64. 2002..We will discuss how the integration of conventional and molecular cytogenetics with gene expression profiling has confirmed past observations and, yet fundamentally changed the way we view the disease... - High-dose therapy and immunomodulatory drugs in multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Semin Oncol 29:26-33. 2002..Careful scrutiny of gene expression will also help in the identification of unrecognized targets for therapeutic intervention... - A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcriptMadhumita Santra
Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:2374-6. 2003..These data indicate that the t(4;14)(p16;q32) and loss of FGFR3 occurred at a very early stage and suggest that activation of MMSET, not FGFR3, may be the critical transforming event of this recurrent translocation... - Overview of biological database mapping services for interoperation between different 'omics' datasetsShweta S Chavan
University of Arkansas Little Rock University of Arkansas Medical Sciences Joint Bioinformatics Program, AR 72204, USA
Hum Genomics 5:703-8. 2011..This review presents the publicly available web-based biological database identifier converters, with comparison of their usage, input and output formats, and the types of available query and target database identifier types... - Proteasome inhibitors and bone diseaseYa Wei Qiang
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Semin Hematol 49:243-8. 2012..This review will discuss the function of PIs in stimulating bone formation and suppression of bone resorption, and the mechanism underlying this process that leads to inhibition bone disease in MM patients... - Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 101:3849-56. 2003.... - NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responsesFrits van Rhee
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, 4301 West Markham, no 776, Little Rock, AR 72205, USA
Blood 105:3939-44. 2005..The pool of NY-ESO-1-specific cytotoxic T cells expands easily on NY-ESO-1 peptide stimulation and is functionally active. NY-ESO-1 should therefore be an ideal tumor target antigen for immunotherapy of patients with poor-prognosis MM... - Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapyAlessandro D Santin
Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Virology 331:269-91. 2005.... - Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1qJeffrey R Sawyer
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Genes Chromosomes Cancer 42:95-106. 2005..We have designated this type of instability as a jumping segmental duplication... - Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapyAlessandro D Santin
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
Int J Cancer 112:14-25. 2004..NOVA. These results, obtained with highly purified primary cultures of ovarian cancer, highlight important molecular features of OSPC and may provide a foundation for the development of new type-specific therapies against this disease... - Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 ampliconJeffrey R Sawyer
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72204, USA
Br J Haematol 147:484-94. 2009..Our findings provide evidence for a novel BFB mechanism involving 1q12 pericentromeric breakage in the amplification of a large number of genes within a 1q12 approximately 23 amplicon... - Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapiesBart Barlogie
Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 107:2633-8. 2006..The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma... - High heparanase activity in multiple myeloma is associated with elevated microvessel densityThomas Kelly
Departments of Pathology, Myeloma Institute for Research and Therapy, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
Cancer Res 63:8749-56. 2003.... - Treatment of multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Blood 103:20-32. 2004..Fundamental and clinical research should, therefore, focus on the molecular and biologic mechanisms of treatment failure in the high-risk subgroup... - Primer on medical genomics. Part IX: scientific and clinical applications of DNA microarrays--multiple myeloma as a disease modelJohn Shaughnessy
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA
Mayo Clin Proc 78:1098-109. 2003.... - The Arkansas approach to therapy of patients with multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, UAMS, Little Rock, AR, USA
Best Pract Res Clin Haematol 20:761-81. 2007.... - Thalidomide and hematopoietic-cell transplantation for multiple myelomaBart Barlogie
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
N Engl J Med 354:1021-30. 2006..High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival... - Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3Yuemeng Dai
Department of Otolaryngology Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, USA
Clin Lymphoma Myeloma Leuk 11:490-7. 2011..It was demonstrated that metallopanstimulin-1 (MPS-1, RPS27) inhibited the growth of tumors formed by head and neck squamous cell carcinoma cells and reduced paxillin gene expression... - Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profilingFenghuang Zhan
Donna D and m Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Semin Hematol 40:308-20. 2003..Here we discuss recent progress made in the development of molecular-based diagnostics and prognostics for MM through the dissection of the transcriptome of PCs from healthy individuals and patients with MM and other PC dyscrasias... - Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell developmentFenghuang Zhan
Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
Blood 101:1128-40. 2003..000 09). MM1 showed no significant linkage with normal cell types studied. Thus, genes whose expression is linked to distinct transitions in late-stage B-cell differentiation can be used to classify MM... - Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
Blood 99:1745-57. 2002..Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM... - Gene expression profiling and multiple myelomaJohn Shaughnessy
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences, Little Rock, AR, USA
Best Pract Res Clin Haematol 18:537-52. 2005..Expression profiling has also led to the identification of a number of new therapeutic targets not only in myeloma cell survival but also in the pathogenesis of the osteolysis which is a hallmark of this disease... - CGO: utilizing and integrating gene expression microarray data in clinical research and data managementKlaus Bumm
Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics and Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
Bioinformatics 18:327-8. 2002.... - Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myelomaSusann Szmania
Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
J Immunother 30:847-54. 2007..MAGE-A3 immunization may be a useful adjunct to high dose melphalan-based peripheral blood stem cell transplant, providing a new therapeutic option for high-risk MM... - Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profilingJeffrey Haessler
Cancer Research and Biostatistics, Seattle, Washington, USA
Clin Cancer Res 13:7073-9. 2007..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma... - Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cellsUnn Merete Fagerli
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway
Blood 111:806-15. 2008..In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells... - Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathyRadek Spisek
Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
J Exp Med 204:831-40. 2007..Harnessing immunity to antigens expressed by tumor progenitor cells may be critical for prevention and therapy of human cancer... - Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathwayJürgen Knobloch
Institut für Entwicklungs und Molekularbiologie der Tiere, Universitat Dusseldorf, Universitatsstrasse 1, 40225 Dusseldorf, Germany
FASEB J 21:1410-21. 2007..From this, we conclude that perturbing of Bmp/Dkk1/Wnt signaling is central to the teratogenic effects of thalidomide... - Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Cell 12:115-30. 2007..These data demonstrate that addiction to the NF-kappaB pathway is frequent in myeloma and suggest that IKKbeta inhibitors hold promise for the treatment of this disease... - Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myelomaJianfei Qian
Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 110:1587-94. 2007..Hence, our study identifies DKK1 as a potentially important antigen for immunotherapy in MM... - The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyYang Yang
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Blood 110:2041-8. 2007.... - Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myelomaShigeyuki Matsui
Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshida konoe cho, Sakyo ku, Kyoto, Japan
Stat Med 27:1106-20. 2008..Application of such clustering to the data set from a clinical study for patients with multiple myeloma and associated microarrays is given... - High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasoneFenghuang Zhan
Blood 111:968-9. 2008 - High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee
Blood 110:827-32. 2007..65, P = .003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease-and steeper reductions after therapy identified patients with inferior survival... - Cancer: An unexpected addictionJohn D Shaughnessy
Nature 454:172-3. 2008 - Duration of survival in patients with myeloma treated with thalidomideBart Barlogie
N Engl J Med 359:210-2. 2008 - High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patientsDaniel R Carrasco
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Cell 9:313-25. 2006.... - CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi
Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Clin Cancer Res 14:2775-84. 2008....
Research Grants
- Molecular Diagnosis and Prognosis of Multiple MyelomaJohn Shaughnessy; Fiscal Year: 2004..Thus, the work proposed supports the goals of an R33 project funded through PAR-01-106 (Applications of Innovative Technologies for the Molecular Analysis of Cancer). ..